Overview

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2024-11-30

Target enrollment:

Participant gender:

Summary

This phase IIa trial studies how well rintatolimod and pembrolizumab works in treating patients with colorectal cancer that does not respond to treatment (refractory), has spread to other places in the body (metastatic), or otherwise cannot be removed by surgery (unresectable). Rintatolimod is an immuno-oncology agent that can stimulate the immune system. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rintatolimod and pembrolizumab together may work better than standard of care in treating patients with colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Roswell Park Cancer Institute

Collaborators:

Merck Sharp & Dohme Corp.
National Cancer Institute (NCI)

Treatments:

Pembrolizumab
Poly I-C
poly(I).poly(c12,U)